What is the price of ICPT stock?
One share of ICPT stock can currently be purchased for approximately $14.36. How much money does Intercept Pharmaceuticals make? Intercept Pharmaceuticals has a market capitalization of $424.34 million and generates $312.69 million in revenue each year.
What does a hold rating mean for Intercept Pharmaceuticals (ICPT)?
A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICPT, but not buy additional shares or sell existing shares. View analyst ratings for Intercept Pharmaceuticals or view top-rated stocks. How has Intercept Pharmaceuticals' stock price been impacted by COVID-19?
Where can I buy Intercept Pharmaceuticals (ICPT)?
Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Intercept Pharmaceuticals' stock price today?
What are analysts'price targets for Intercept Pharmaceuticals'stock?
17 Wall Street analysts have issued 1-year price targets for Intercept Pharmaceuticals' stock. Their forecasts range from $10.00 to $67.00. On average, they anticipate Intercept Pharmaceuticals' share price to reach $29.67 in the next year. This suggests a possible upside of 106.6% from the stock's current price.
Is Intercept Pharmaceuticals a buy right now?
12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last twelve months. There are c...
When is Intercept Pharmaceuticals' next earnings date?
Intercept Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecas...
How were Intercept Pharmaceuticals' earnings last quarter?
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) issued its quarterly earnings results on Friday, May, 6th. The biopharmaceutical company reported ($0...
What guidance has Intercept Pharmaceuticals issued on next quarter's earnings?
Intercept Pharmaceuticals issued an update on its FY 2022 earnings guidance on Wednesday, March, 30th. The company provided EPS guidance of for the...
What price target forecast have analysts set for ICPT?
12 analysts have issued 12-month price targets for Intercept Pharmaceuticals' stock. Their forecasts range from $10.00 to $67.00. On average, they...
Who are Intercept Pharmaceuticals' key executives?
Intercept Pharmaceuticals' management team includes the following people: Mr. Jerome B. Durso , Pres, CEO & Director (Age 54, Pay $853.17k) Dr....
What is Mark Pruzanski's approval rating as Intercept Pharmaceuticals' CEO?
32 employees have rated Intercept Pharmaceuticals CEO Mark Pruzanski on Glassdoor.com . Mark Pruzanski has an approval rating of 80% among Interce...
Who are some of Intercept Pharmaceuticals' key competitors?
Some companies that are related to Intercept Pharmaceuticals include Amgen (AMGN) , Gilead Sciences (GILD) , Regeneron Pharmaceuticals (REGN) ,...
What other stocks do shareholders of Intercept Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Th...
What is the ICPT symbol?
What is the P/E ratio of intercept pharmaceuticals?
Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."
What is a market beat rating?
The P/E ratio of Intercept Pharmaceuticals is -5.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
What is the FY 2021 earnings guidance?
MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote “Outperform” if you believe ICPT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ICPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Where is intercept pharmaceuticals located?
Intercept Pharmaceuticals issued an update on its FY 2021 earnings guidance on Thursday, July, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $325 million-$340 million, compared to the consensus revenue estimate of $334.31 million.
Does Intercept Pharmaceuticals pay dividends?
Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY , 10001. The biopharmaceutical company can be reached via phone at (646) 747-1000, via email at [email protected], or via fax at 646-747-1001.
Intercept Pharmaceuticals (NASDAQ:ICPT) Earnings Estimates
Intercept Pharmaceuticals does not currently pay a dividend.
Intercept Pharmaceuticals (NASDAQ:ICPT) Earnings Frequently Asked Questions
Enter your email address below to receive the latest news and earnings results for ICPT and its competitors with MarketBeat's FREE daily newsletter.
Quarter in Detail
Intercept Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 24th, 2022 based off last year's report dates. Learn more on ICPT's earnings history
2021 Guidance Upped
Total revenues generated in the quarter comprised only Ocaliva (obeticholic acid or OCA) net sales. Net sales came in at $66.6 million in the United States and $26.2 million outside the country.
Other Updates
Ocaliva net sales are now projected between $355 million and $370 million (earlier guidance: $325 million to $340 million).
Our Take
The prescribing information for lead drug, Ocaliva, in the United States has been updated. The update to the prescribing information was prompted by cases submitted to the FDA’s Adverse Event Reporting System and published in the medical literature.
Intercept Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
The lower-than-expected loss in the third quarter was encouraging. The company’s effort to develop a treatment for NASH despite setbacks is positive.
